FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HERSHBERG ROBERT						2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX]									all app Direc	tor	ng Pers	10% Ov	vner	
	CURSION I	(First) (Middle) RSION PHARMACEUTICALS GRANDE STREET				3. Date of Earliest Transaction (Month/Day/Year) 07/01/2021										er (give title v)		Other (s below)	респу	
(Street) SALT LA CITY (City)	U'J		4101 		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	Form	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson				
		Table	I - Nor	n-Deriva	tive \$	Secu	rities	Acq	uired,	, Dis	posed of	, or E	Benefi	cially	Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution y/Year) if any		ution Date,		3. 4. Securitie Transaction Code (Instr. 8) 5.		es Acquired (A Of (D) (Instr. 3,		4 and Secur Benef		cially I Following	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Code	v	Amount	(A) (D)					or Pri	се	Transa	action(s) 3 and 4)			(111341. 4)					
Class A Common Stock 07/01/2				2021				A		347(1)	A	\$0	.00(1)	6,597]	D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) o Dispo of (D) (Instr and 5	Expiration (Month/Darrities ired rosed)		ion Da		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. Price o Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	wnership orm: irect (D) r Indirect	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amour or Number of Shares	er						

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

/s/ Nathan Hatfield, attorney-

in-fact

** Signature of Reporting Person Date

07/06/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.